Neuroprotection - new promising treatment for glaucomatous optic neuro(2)
So, Jiang and his colleagues took advantage of drug delivery vehicle- Biodegradable microspheres to investigated the potential survival enhancing role for glial cell line-derived neurotrophic factor (GDNF) in experimental glaucoma[11]. First, Jiang et al. showed that biodegradable microspheres persist in the vitreous in rats for at least 6 weeks.Next, they injected GDNF and control microspheres into vitreous cavity in rats with elevated IOP. At 8 weeks following IOP elevation, retinas and optic nerves were collected and analyzed by immunohistochemistry and histology. Jiang et al. showed that the pressure levels rose gradually, stabilizing at 3 weeks at about twice normal values in all experimental groups. Immunolabeling for GDNF and its receptors showed that these proteins were localized, in part, to RGC. In retinas treated with GDNF spheres, the authors reported decreased nerve head cupping, increased nerve fiber layer thickness, significantly increased inner plexiform layer thickness, more importantly, significantly increased RGCs and axonal survival. In addition, retinal glial activation, which has been proposed as an important factor contributing to RGC death in glaucoma[12-13],significantly reduced[6].
, http://www.100md.com
These results provide the best evidence so far that sustained GDNF delivery by biodegradable microspheres offers significant neuroprotection to injured RGC in experimental glaucoma. Although these results provide hope for the glaucomatous optic neuropathy, they also have implications for treatment strategies in other retinal degenerative diseases.
References
[1] Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90:262-267
, 百拇医药
[2] A.H. Dahlmann-Noor, S. Vijay, G. Astrid Limb and P.T. Khaw. Strategies for optic nerve rescue and regeneration in glaucoma and other optic neuropathies. Drug Discovery today 2010;15:287-299
[3] Kuehn MH, Fingert JH, and Kwon YH. Retinal ganglion cell death in glaucoma: mechanisims and neuroprotective strategies. Ophthalmology Clinics of North America 2005; 18: 383-395
[4] Levin LA. Neuroprotection and regeneration in glaucoma. Ophthalmol Clin N Am, 2005; 18: 585-596
, http://www.100md.com
[5] Ritch R. Complementary therapy for the treatment of glaucoma: a perspective. Ophthalmol Clin North Am 2005; 18: 597-609
[6] Jiang C, Moore M, Zhang X, Klassen H, Langer R, Young M. Intravitreal Injections of GDNF-Loaded Biodegradable Microspheres are Neuroprotective in a Rat Model of Glaucoma. Molecular Vision 2007; 13:1783-1792
作者单位:100853 Department of Ophthalmology, the Chinese PLA General Hospital, Beijing,China, 百拇医药(Jian-He Xiao, Mao-Nian Zhang)
, http://www.100md.com
These results provide the best evidence so far that sustained GDNF delivery by biodegradable microspheres offers significant neuroprotection to injured RGC in experimental glaucoma. Although these results provide hope for the glaucomatous optic neuropathy, they also have implications for treatment strategies in other retinal degenerative diseases.
References
[1] Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90:262-267
, 百拇医药
[2] A.H. Dahlmann-Noor, S. Vijay, G. Astrid Limb and P.T. Khaw. Strategies for optic nerve rescue and regeneration in glaucoma and other optic neuropathies. Drug Discovery today 2010;15:287-299
[3] Kuehn MH, Fingert JH, and Kwon YH. Retinal ganglion cell death in glaucoma: mechanisims and neuroprotective strategies. Ophthalmology Clinics of North America 2005; 18: 383-395
[4] Levin LA. Neuroprotection and regeneration in glaucoma. Ophthalmol Clin N Am, 2005; 18: 585-596
, http://www.100md.com
[5] Ritch R. Complementary therapy for the treatment of glaucoma: a perspective. Ophthalmol Clin North Am 2005; 18: 597-609
[6] Jiang C, Moore M, Zhang X, Klassen H, Langer R, Young M. Intravitreal Injections of GDNF-Loaded Biodegradable Microspheres are Neuroprotective in a Rat Model of Glaucoma. Molecular Vision 2007; 13:1783-1792
作者单位:100853 Department of Ophthalmology, the Chinese PLA General Hospital, Beijing,China, 百拇医药(Jian-He Xiao, Mao-Nian Zhang)